An Interagency Collaboration to Facilitate Development of Filovirus Medical Countermeasures

Viruses

Nicole Kilgore¹ 

[1] Chemical Biological Medical Systems Joint Vaccine Acquisition Program, 1564 Freedman Dr, Fort Detrick, MD 21702, USA; E-mail:

关键词: biodefense;    Ebola;    ebolavirus;    FANG;    Filoviridae;    filovirus;    Filovirus Animal Non-Clinical Group;    Marburg virus;    marburgvirus;    medical countermeasures;   

DOI  :  10.3390/v4102312

来源: mdpi

【 摘 要 】

The Filovirus Animal Non-Clinical Group (FANG) is a US interdepartmental and interagency group established to support and facilitate the advanced development of filovirus Medical Countermeasures (MCM), both vaccines and therapeutics. It is co-led by one representative from the Department of Defense (DoD), the first author, and one from the Department of Health and Human Services (HHS), the second author. The FANG membership includes operational level program staff and Subject Matter Experts (SME) from performing organizations as well as scientific staff and program managers from DoD and HHS funding and regulatory agencies. Focus areas include animal models, assays, reagents, product manufacture and characterization, and other interagency product development issues that will support Food and Drug Administration (FDA) licensure of safe and effective filovirus MCMs. The FANG continues to develop strategies to address broadly applicable and interagency product development challenges relevant to filovirus MCM development. This paper summarizes FANG structure and accomplishments and is meant to heighten community awareness of this government-led collaborative effort.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.